腾盛博药-B(02137)上涨20.25%,报1.9元/股

金融界
24 Feb

2月24日,腾盛博药-B(02137)盘中上涨20.25%,截至11:19,报1.9元/股,成交2518.5万元。

腾盛博药生物科技有限公司主要业务是针对未被满足的病人需求和有限的治疗手段,开发针对感染性疾病和中枢神经系统疾病的创新疗法。该公司成立于2018年,现业务遍布罗利-达勒姆、旧金山湾区和中国的北京与上海,于2021年在香港交易所挂牌上市,股票代码为2137.HK。

截至2023年年报,腾盛博药-B营业总收入61.7万元、净利润-1.75亿元。

8月19日,腾盛博药-B披露2024财年中报。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10